αamylase

α-Amylase-IN-1 is an α-Amylase inhibitor (IC50: 0.5509 μM). α-Amylase-IN-1 has antioxidant activity with an IC50 value of 53.49 μM for scavenging of DPPH free radicals, and can be used in the study of diabetes and oxidative stress-related diseases.

α-Amylase α-Glucosidase-IN-4 (compound 5), a dual inhibitor targeting α-amylase (Amylases) and α-glucosidase (Glucosidase), exhibits potent inhibition with IC50 values of 1.10 μM and 0.15 μM respectively, and is noted for its potential antidiabetic activity [1].

α-Amylase α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50 values of 17.0 µM and 40.1 µM, respectively, and demonstrates anti-hyperglycemic activities [1].

β-Amylase exhibits significant starch-degrading activity and is utilized in a range of biochemical studies [1].

Bacterial α-Amylase, often employed in biochemical research [1], facilitates the hydrolysis of internal α-1,4-glycosidic bonds within starch, resulting in low molecular weight products such as glucose, maltose, and maltotriose.

α-Amylase α-Glucosidase-IN-1 (compound 33) is an effective inhibitor of α-amylase and α-glucosidase, with IC50 values of 2.01 and 2.09 μM, respectively. Kinetic studies predict that α-Amylase α-Glucosidase-IN-1 has potential anti-hyperglycemia properties [1].

α-Amylase α-Glucosidase-IN-5 (compound 4l) functions as a dual inhibitor, effectively inhibiting both α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50 values of 5.96 μM and 1.62 μM, respectively, exhibiting potential for antidiabetic activity [1].

α-Amylase-IN-4 (Compd 10y) exhibits the highest amylase inhibition with an IC50 value of 17.83 ± 0.14 μg mL [1].

α-Glucosidase-IN-3, an oxime ester derivative of oleanolic acid (OA), exhibits inhibitory activity against α-glucosidase (IC50 = 1.28 µM) and α-amylase (IC50 = 3.8 µM).

α-Amylase α-Glucosidase-IN-7 (Compound 3f) serves as a competitive inhibitor for the enzymes α-glucosidase and α-amylase, exhibiting IC50 values of 18.52 µM and 20.25 µM, respectively. Additionally, it effectively inhibits AChE and BChE, with IC50 values of 9.25 µM and 10.06 µM, respectively. This compound is useful in research related to diabetes and Alzheimer’s [1].

α-Amylase α-Glucosidase-IN-3 (Compound 17) is a dual inhibitor of α-Amylase and α-Glucosidase, with IC50 values of 0.70 μM and 1.10 μM, respectively, applicable for type-II diabetes mellitus research [1].

α-Amylase-IN-5 (compound 3a) acts as an α-amylase inhibitor and exhibits an inhibition concentration (IC 50) of 18.8 mM [1].

α-Amylase α-Glucosidase-IN-2 (compound 5) exhibits strong inhibition of α-amylase and α-glucosidase enzymes, with IC50 values of 13.02 μM and 13.09 μM, respectively, showing promise for investigating diabetic complications [1].

α-Amylase-IN-3 (Compound 4) is a non-competitive inhibitor of α-Amylase with an IC50 value of 18.04 μM. It exhibits radical scavenging activities with IC50 values of 16.04 μM for DPPH and 16.99 μM for ABTS. α-Amylase-IN-3 demonstrates good protein–ligand interaction characteristics for α-Amylase, and may possess pharmacological activities, such as anti-oxidative and anti-inflammatory properties, contributing to the research of diabetes and oxidative stress-associated diseases[1].

α-Amylase, a hydrolase enzyme, catalyzes the hydrolysis of internal α-1,4-glycosidic linkages in starch, producing glucose and maltose.

Amylase (Diastase) is any one of a group of enzymes which catalyses the breakdown of starch into maltose.